Antiretroviral therapy and declining AIDS mortality in New York City

Journal of Urban Health

Volumn 77, Issue 3, 2000, Pages 492-500

  Wong, T ^a   Chiasson, M A ^a   Reggy, A ^a   Simonds, R J ^a   Heffess, J ^a   Loo, V ^a  

^a LAB CENTRE FOR DISEASE CONTROL   (Canada)

Author keywords

Antiretroviral Therapy; HAART; Mortality; Protease Inhibitors

Indexed keywords

ANTIRETROVIRUS AGENT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; CONTROLLED STUDY; FEMALE; HEALTH INSURANCE; HUMAN; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SEX DIFFERENCE; SURVIVAL; VIRUS TRANSMISSION;

EID: 0033841201     PISSN: 10993460     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02386756     Document Type: Article

References (22)

1. Declining AIDS mortality in New York City
2. Rapid change in the use of antiretroviral agents and improvement in a population of HIV-infected patients: France, 1995-1997
3. Effectiveness of potent antiretroviral therapy on time to AIDS and death in men with known HIV infection duration. Multicenter AIDS Cohort Study Investigators
4. Cascade Collaboration. Survival after introduction of HAART in people with known duration of HIV-1 infection
5. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less
6. Randomized placebo - Controlled trial of ritonavir in advanced HIV-1 disease. The Advanced HIV Disease Ritonavir Study
7. Vital statistics, instructions for classifying the underlying cause of death
8. Impact of protease inhibitor containing regimens on the risk of developing opportunistic infections and mortality in the CPCRA 034/ ACTG 277 Study
9. Natural history of HIV infection in the era of combination antiretroviral therapy
10. Impact of new antiretroviral combination therapies in HIV infected patients in Switzerland: Prospective multicentre study
11. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection
12. Changing patterns of mortality across Europe in patients infected with HIV-1. EuroSIDA Study Group
13. Effects of antiretroviral therapy and opportunistic illness primary chemoprophylaxis on survival after AIDS diagnosis. Adult/Adolescent Spectrum of Disease Group
14. Differences in access to zidovudine (AZT) among symptomatic HIV-infected persons
15. The use of health services by women with HIV infection
16. Racial differences in the use of drug therapy for HIV disease in an urban community
17. The effects of immune status and race on health service use among people with HIV disease
18. Improved survival among HIV-infected patients after initiation of triple-drug antiretroviral regimens
19. Increasing survival time after AIDS in Italy: Therole of new combination antiretroviral therapies. Tuscany AIDS Study Group
20. Differential decline in AIDS mortality by gender and race/ethnicity in New York City